Canada Markets open in 4 hrs 15 mins

Rakovina Therapeutics Inc. (RKV.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.18000.0000 (0.00%)
At close: 09:30AM EDT

Rakovina Therapeutics Inc.

1008 Beach Avenue
Suite 105
Vancouver, BC V6E 1T7

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey A. Bacha B.Sc., M.B.A.Exec. ChairmanN/AN/A1968
Dr. Mads DaugaardPres & Chief Scientific OfficerN/AN/AN/A
Mr. David Hyman CA, CBVCFO & Corp. Sec.N/AN/A1973
Dr. John Langlands Ph.D.Chief Operating OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Rakovina Therapeutics Inc., a biopharmaceutical company, focuses on development of cancer therapies based on novel DNA-damage response technologies. The company's lead pipeline products include kt-2000, the next generation oral targeted small molecule PARP inhibitors; kt-3000, a class of small-molecule drug candidates to overcome and prevent resistance to treatment with first generation DDRi; and kt-4000 to cause targeted DNA-damage to a tumor cell's DNA while simultaneously inhibiting the tumor's DNA damage response. Rakovina Therapeutics was founded in 2020 and is headquartered in Vancouver, Canada.

Corporate Governance

Rakovina Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.